Standard BioTools (LAB) Projected to Release Earnings on Tuesday

Key Points

• Standard BioTools is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.02 per share and revenue of approximately $18.80 million; the earnings call is scheduled for November 5 at 4:00 p.m. ET.
• The company’s previous quarter fell short of expectations, with an adjusted loss of $0.07 per share versus the $0.01 expected and revenue of $20.10 million versus the $20.80 million consensus.
• Investor sentiment remains weak: shares recently opened at $0.60 near their 52-week low, while analysts assign the stock a consensus “Reduce” rating and a $1.35 price target.

Standard BioTools (NASDAQ:LAB - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Standard BioTools to announce earnings of ($0.02) per share and revenue of $18.80 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Standard BioTools (NASDAQ:LAB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.06). Standard BioTools had a net margin of 100.36% and a negative return on equity of 7.57%. The company had revenue of $20.10 million during the quarter, compared to the consensus estimate of $20.80 million.

Standard BioTools Price Performance

LAB opened at $0.60 on Tuesday. The firm has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.94. Standard BioTools has a 52 week low of $0.59 and a 52 week high of $1.72.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Standard BioTools from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Standard BioTools presently has a consensus rating of "Reduce" and a consensus price target of $1.35.

About Standard BioTools

Standard BioTools Inc NASDAQ: LAB develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.

The company's offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.